The trial, designed as a safety study, successfully showed that BrachySil, in combination with standard chemotherapy (gemcitabine), was well tolerated with no clinically significant adverse events related to BrachySil. Data showed disease control in 82% of patients and an overall median survival of 309 days.
BrachySil was found to be easily deliverable by endoscopic ultrasound. BrachySil is a novel oncology product which comprises a combination of BioSilicon, a proprietary porous silicon, and the isotope 32Phosphorus, a proven anti-cancer therapeutic.